Quest Laboratories is a pharmaceutical factory that makes the pills, syrups and ointments you find in chemists’ shops and government hospitals - it was founded in 1998 in Pithampur, Madhya Pradesh, and listed on the NSE’s small-company platform in 2024. Everything the company does flows from a single manufacturing campus and a simple operating rhythm: hold regulatory approvals for a very wide catalogue of medicines, then route those products to customers through three distinct channels - franchise salespeople who carry the brand to doctors, bulk government tenders, and export traders - so that the same factory output reaches many different buyers without the company having to build its own consumer brand or retail network.
Business segments
A single manufacturing engine that makes over a thousand approved formulations, sold through three distribution channels - franchise, government tender and export - with an injectable facility under construction as its next act.
1. Pharmaceutical formulations: the factory that supplies everyone
One plant in Pithampur makes tablets, liquids, powders and ointments across more than a dozen therapy areas, then pushes them out through franchise partners, public-sector tenders and export traders - three routes that share the same production lines.
- A catalogue built for breadth, not blockbusters - the company holds approvals for over 1,300 formulations and keeps 394-plus products active, manufacturing 250-300 different formulations each year depending on what the market is asking for. That means it can supply antibiotics, antimalarials, diabetes pills, antidepressants, respiratory medicines and antiallergics all from the same building, so no single drug or therapy makes or breaks the business.
- Franchise reps carry the brand to doctors - under the Propaganda Cum Distribution (PCD) model, the company appoints regional franchise partners who promote Quest’s ethical and generic drugs to prescribing doctors in their territory, giving the company a sales force without putting one on its own payroll.
- Government orders fill the plant with guaranteed volumes - the company bids for state and central government tenders, securing bulk orders for public hospitals and institutions at pre-agreed prices, which provides predictable production runs alongside the more variable franchise business.
- Export traders buy from the factory gate - through the merchant export model, international buyers purchase finished medicines ex-works from Pithampur, so Quest gets foreign sales without having to register products abroad or manage overseas distribution itself. The company also makes medicines for other firms under contract manufacturing arrangements.
- The plant runs on in-house testing and development - the factory houses its own formulation development, quality control and product stability labs, and the company puts 2% of revenue into R&D for formulation and dosage work, so it can develop new variants and test raw materials without outsourcing. Daily capacity stands at more than 9 million tablets and over 1,000 kg of ointments.
2. Injectable facility: the next factory line, built for regulated markets
A USFDA-compliant injectable plant is being built on the same Pithampur campus to add oncology vials, ampoules and dry injections - products that command higher barriers to entry and open doors to tightly regulated export markets.
- Built, not bought - the company is constructing the injectable lines from the ground up at its existing site, with dedicated capacity for oncology drugs, ampoules, vials and dry injections, alongside a parallel capsule production line.
- USFDA compliance is the whole point - the dry injection and ampoule line is being developed to meet United States Food and Drug Administration standards, which means the facility is designed from the start for markets where regulatory approval is the hardest to get and the most valuable once obtained.
- Funded by the 2024 IPO - the capital expenditure for the injectable plant and other machinery is being drawn from the ₹26 crore raised in the public offering, of which roughly ₹2.7 crore had been spent by the end of FY25, leaving the bulk of the funds still to be deployed.
3. International exports: a Myanmar anchor deal and a scatter of African orders
Export sales began in 2025, anchored by a five-year exclusive distribution agreement in Myanmar and supplemented by spot orders from a dozen African and Southeast Asian countries - an early-stage push that uses a partner’s local legs rather than building Quest’s own.
- Registration costs are shared, IP stays home - Quest pays the Myanmar FDA product registration costs (half upfront, half after dossier submission), but retains all intellectual property, formulation know-how and manufacturing processes; the distributor can only use that IP for registration and marketing in Myanmar.
- African orders are small but multiplying - the company has received orders from Angola, Mali, Niger, Nigeria, Togo, Burkina Faso and Benin, and is developing markets in Kenya and East Africa, with a ₹2 crore order from Angola landing in May 2025.
- Payment before dispatch - export orders require 30% advance on the purchase order and the remaining 70% before the goods leave the factory, or payment via an irrevocable letter of credit from a recognised international bank, so Quest carries minimal counterparty risk on these sales.
Group structure and partners
Quest Laboratories is a standalone company with no subsidiaries, associates or joint ventures - it operates a single factory, sells through arm’s-length franchise and export partners, and has no inter-company loans or investments.
- The Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures, and has not raised any loans during the year on the pledge of securities held in its subsidiaries, associates or joint ventures.
- The sole international distribution partner is TOPS Co. Ltd. in Myanmar, appointed under a five-year exclusive agreement that is not a related-party transaction.
- Shares are listed on the NSE SME Emerge Platform and held in dematerialised form with CDSL and NSDL; the registrar and share transfer agent is Bigshare Services Pvt Ltd.